![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Anzahl der Publikationen: 3
2018
Braciak, Todd A.; Roskopf, Claudia C.; Wildenhain, Sarah; Fenn, Nadja C.; Schiller, Christian B.; Schubert, Ingo A.; Jacob, Uwe; Honegger, Annemarie; Krupka, Christina; Subklewe, Marion; Spiekermann, Karsten; Hopfner, Karl-Peter; Fey, Georg H.; Aigner, Michael; Krause, Stefan; Mackensen, Andreas und Oduncu, Fuat S.
(2018):
Dual-targeting triplebody 33-16-123 (SPM-2) mediates effective redirected lysis of primary blasts from patients with a broad range of AML subtypes in combination with natural killer cells.
In: Oncoimmunology, Bd. 7, Nr. 9, e1472195
2016
Schiller, Christian B.; Braciak, Todd A.; Fenn, Nadja C.; Seidel, Ursula J. E.; Roskopf, Claudia C.; Wildenhain, Sarah; Honegger, Annemarie; Schubert, Ingo A.; Schele, Alexandra; Lämmermann, Kerstin; Fey, Georg H.; Jacob, Uwe; Lang, Peter; Hopfner, Karl-Peter und Oduncu, Fuat S.
(2016):
CD19-specific triplebody SPM-1 engages NK and gd T cells for rapid and efficient lysis of malignant B-lymphoid cells.
In: Oncotarget, Bd. 7, Nr. 50: S. 83392-83408
2013
Braciak, Todd A.; Wildenhain, Sarah; Roskopf, Claudia C.; Schubert, Ingo A.; Fey, Georg H.; Jacob, Uwe; Hopfner, Karl-Peter und Oduncu, Fuat S.
(2013):
NK cells from an AML patient have recovered in remission and reached comparable cytolytic activity to that of a healthy monozygotic twin mediated by the single-chain triplebody SPM-2.
In: Journal of Translational Medicine
11:289
[PDF, 3MB]